JAK Inhibitors Revolutionize Dermatology Treatments at SDPA Conference
The landscape of dermatological treatments is evolving rapidly, particularly with the introduction of Janus kinase (JAK) inhibitors. Since the U.S. Food and Drug Administration (FDA) approved ruxolitinib cream in 2021,…